BioNxt Solutions (XTER:BXT) 1-Year Sharpe Ratio: -0.98 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:BXT BioNxt Solutions Inc XTER:BXT
31 GF Score
Price €0.18
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions 1-Year Sharpe Ratio?

BioNxt Solutions XTER:BXT -9.27% 31 1-Year Sharpe Ratio is -0.98 as of Aug. 13, 2026. GuruFocus rates XTER:BXT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-13), BioNxt Solutions's 1-Year Sharpe Ratio is -0.98.

BioNxt Solutions  (XTER:BXT) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

BioNxt Solutions 1-Year Sharpe Ratio Related Terms

XTER:BXT vs ZTS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNxt Solutions 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's 1-Year Sharpe Ratio falls into.


XTER:BXT
31GF Score
BioNxt Solutions Inc XTER:BXT
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNxt Solutions 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.98 mean?
BioNxt Solutions (XTER:BXT) has a 1-Year Sharpe Ratio of -0.98 as of Aug. 13, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for BioNxt Solutions and its competitors.
Is BioNxt Solutions' 1-Year Sharpe Ratio too high?
BioNxt Solutions' current 1-Year Sharpe Ratio is -0.98. Overall, BioNxt Solutions has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' 1-Year Sharpe Ratio compare to ZTS?
BioNxt Solutions' 1-Year Sharpe Ratio of -0.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for BioNxt Solutions and its competitors. BioNxt Solutions's current 1-Year Sharpe Ratio is -0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (XTER:BXT) has a current 1-Year Sharpe Ratio of -0.98. The current 1-Year Sharpe Ratio is -0.98. BioNxt Solutions' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For BioNxt Solutions (XTER:BXT), the current 1-Year Sharpe Ratio is -0.98 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNxt Solutions Business Description

Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score

Get the complete analysis for XTER:BXT

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price